You spoke and we listened! We have updated our catalogue and some of our EQA schemes shaped by your insights to better support laboratories worldwide.
We have launched new EQA schemes: Skeletal Dysplasia (Genomic & inherited disorders), Comprehensive Genomic Profiling (Molecular Pathology) and CYP2C19 (Point of care testing)
We've introduced Early Bird pricing to help support your lab's goals. Get in touch with us to learn more about the offer and how it can benefit you.
Continuing with the changes made in 2025, we have rolled out more flexible EQA's that give participants the option to choose a test strategy that better meets their needs.
We are increasing the number of schemes for which we offer “virtual” cases, to enable the inclusion of rare genotypes and reduce analysis costs. However, we will still provide cases with corresponding DNA samples for all our EQA schemes, to ensure the whole laboratory pipeline is tested from sample receipt to reporting.
We have introduced multilingual support for its EQA schemes, now accepting submissions in English, French, German, Italian, and Spanish. This update makes participation easier for labs worldwide and ensures feedback is clearer and more relevant.
We have improved our online catalogue to allow purchasing of additional samples (where available); these can now be purchased with the scheme without having to order a separate item.
Our mission is to support laboratories worldwide in delivering excellence in molecular diagnostics—and we believe knowledge is the key. With the launch of our new catalogue, we’re also introducing a fresh webinar series, expanded case studies, and practical tools to help you stay ahead of emerging trends, sharpen your skills, and connect globally. Together, we’re shaping a future where every lab has the insight and confidence to deliver exceptional patient care.
We’re pleased to announce the launch of a new EQA scheme: Skeletal Dysplasia.
As part of our ongoing updates to support evolving laboratory practices, the scope and naming of several EQA schemes have been revised to better accommodate both panel-based testing and targeted testing strategies.
Participants will now be presented with an EQA option (see below) that allows them to select the most appropriate testing strategy for their laboratory.
Schemes affected by this update include:
We’re excited to announce the launch of a new EQA scheme: Comprehensive Genomic Profiling.
Building on the changes introduced in 2025, we’ve expanded our offering with additional EQA schemes that give participants the flexibility to choose a test strategy that best suits their laboratory’s needs.
One of the schemes affected by this update is:
Continuing with the changes made in 2025, we have rolled out more EQA’s that give participants the option to choose a test strategy that better meets their needs. The schemes affected are: NGS for somatic SNVs and indels and Sanger sequencing.
We are excited to launch a new EQA for CYP2C19 Point-of-Care Testing (POCT). This EQA is designed to support the accurate and timely identification of CYP2C19 variants in acute clinical settings. This ensures that patients—particularly those presenting with recent ischaemic stroke or transient ischaemic attack (TIA)—receive the most appropriate antiplatelet therapy.
Identifying CYP2C19 poor or intermediate metabolisers enables tailored clopidogrel prescribing, which may improve clinical outcomes and reduce the risk of adverse events.
